进展期胃癌术后辅助化疗加参芪扶正液的疗效观察

Effect Observation of Postoperative Adjuvant Immunochemotherapy for Stage Gastric Cancer

目的: 探讨参芪扶正液+丝裂霉素(MMC) +喃氟啶(FT-207)方案对进展期胃癌术后辅助化疗效果。方法: 将63例治愈根治性切除的进展期胃癌病例,术后随机分为两组:对照组( 33例)术后辅助MMC+FT-207方案化疗, 实验组(30例)术后辅助参芪扶正液+MMC+FT-207方案免疫化疗。分别观察患者一般状态,生存情况。结果:实验组全身乏力,面色苍白,食少纳差,恶心呕吐,腹胀,腹泻等症状明显好与对照组。实验组与对照组3年生存率分别为53. 0%和54. 5%,两组差异无统计学意义;但前者5年生存率为46. 7%,显著高于后者的30. 3%。结论: 参芪扶正液+MMC+FT-207辅助免疫化疗可提高胃癌患者对化疗的耐受性及改善生活质量。

Objective: To investigate the effect of postoperative adjuvant immunochemotherapy with Mitomycin C(MMC)+Tegaful(FT-207)+Shenqifuzhengye(SQFZY) regimen in stage gastric cancer .Methods: Sixty-three patients with gastric cancer who received radical gastrectomy were randomly divided into two groups after operation,immunochemotherapy group(n=30)with MMC+FT-207+SQFZY regimen,and chemotherapy group (n=33)with MMC+FT-207 regimen. The general life status and postoperative survival rate were observed . Results:The life status,such as tiredness,paleness,loss of appetite,nausea and vomiting,flatulence and diarrhea is better in the patients of immunochemotherapy group than that in chemotherapy group.Conclusion:Immunochemotherapy with SQFZY +MMC+FT-207 regimen might enhance tolerance of the patient for chemotherapy and improve their quality of life.